Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 5, 2017

Orthocell starts enrolment in tendon regeneration therapy trial

Australia-based regenerative medicine firm Orthocell has started patient enrolment in a clinical trial of its tendon regeneration therapy Ortho-Autologous Tenocyte Injection (ATI) to treat rotator cuff tendinopathy and shoulder joint tear.

Australia-based regenerative medicine firm Orthocell has started patient enrolment in a clinical trial of its tendon regeneration therapy Ortho-Autologous Tenocyte Injection (ATI) to treat rotator cuff tendinopathy and shoulder joint tear.

The two injuries are reported to decrease the quality of life due to considerable disability, and are said to be a significant burden on healthcare resources.

Ortho-ATI technology is an advanced cellular therapy used on damaged or degenerate tendons resistant to existing conventional therapies.

The clinical trial will compare the effectiveness of Ortho-ATI with the corticosteroid injection in patients who have failed previous traditional treatment options such as injection treatment and physiotherapy.

Orthocell managing director Paul Anderson said: “Demonstrating the efficacy of Ortho-ATI for the treatment of rotator cuff tendinopathy is an important element of our product development and partnering strategy.

"Ortho-ATI is found to be a cost-effective, long-term and durable non-surgical treatment for difficult tendon injuries."

“We expect results to show Ortho-ATI is a durable and effective treatment for degenerative shoulder injuries.”

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

According to results from previous studies, Ortho-ATI is found to be a cost-effective, long-term and durable non-surgical treatment for difficult tendon injuries.

In Australia, New Zealand, and Hong Kong, Ortho-ATI is available with regulatory oversight for patients who have ongoing symptoms after the failure of treatment options such as corticosteroid injections and exercise programmes.

The Ortho-ATI injection involves a small healthy tendon piece being taken from the patient and sent to the firm’s laboratory, where tenocytes are isolated and grown to a clinically significant number.

The cells are then implanted into the affected tissue around four to five weeks after the initial biopsy.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU